围手术期腹腔热灌注化疗治疗胃癌25例

目的]探讨胃癌围手术期(术中和术后早期)腹腔热灌注化疗的可行性、安全性、毒副作用、并发症。方法]对25例进展期胃癌患者行根治性或姑息性切除术;术中行腹腔热灌注化疗(5-氟尿嘧啶 丝裂霉素)1次,术后前4天,每日腹腔热灌注化疗(5-氟尿嘧啶)1次。结果]术中及术后早期行腹腔热灌注化疗成功率为100%,热灌注化疗期间患者生命体征无明显异常。治疗后亦无明显毒副作用和并发症,无治疗相关性死亡。随访8～26个月,2例发生腹腔转移(8%);1例发生肝转移,2例分别于术后8、15个月死于全身广泛转移。结论]胃癌围手术期腹腔热灌注化疗安全可行,毒副作用小,并发症少。

Perioperative Intraperitoneal Hyperthermic Perfusion Chemotherapy in the Treatment for 25 Cases with Gastric Cancer

Purpose] To evaluate the feasibility, safety, toxicity and complication of perioperative (intraoperative and early postoperative) intraperitoneal hyperthermic perfusion chemotherapy (IPHPC) for gastric cancer. Methods] Radical or palliative resection were performed in 25 cases with advanced gastric cancer. The patients underwent IPHPC with 5-Fu and mitomycin once intra IPHPC operation, then received IPHPC with 5-Fu from day 1 to day 4 postoperation. Results] There were no obvious changes in vital signs during perfusion. And there were neither obvious toxicities nor complications after treatment. No therapy related death was found. All the cases were followed up for 8~26 months with 2 peritoneal metastasis (8%), 1 hepatic metastasis(4%), 2 death of extensive metastasis in 8 and 15 months respectively. Conclusion] The perioperative IPHPC for gastric cancer is safe, feasible, and less toxicities and complications.